Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 127

1.

Clinical Potential of Targeting Fibroblast Growth Factor-23 and αKlotho in the Treatment of Uremic Cardiomyopathy.

Law JP, Price AM, Pickup L, Radhakrishnan A, Weston C, Jones AM, McGettrick HM, Chua W, Steeds RP, Fabritz L, Kirchhof P, Pavlovic D, Townend JN, Ferro CJ.

J Am Heart Assoc. 2020 Apr 7;9(7):e016041. doi: 10.1161/JAHA.120.016041. Epub 2020 Mar 26.

PMID:
32212912
2.

Anticoagulant strategies for the patient with chronic kidney disease.

Law JP, Pickup L, Townend JN, Ferro CJ.

Clin Med (Lond). 2020 Mar;20(2):151-155. doi: 10.7861/clinmed.2019-0445.

3.

Association between non-malignant monoclonal gammopathy and adverse outcomes in chronic kidney disease: A cohort study.

Fenton A, Chinnadurai R, Gullapudi L, Kampanis P, Dasgupta I, Ritchie J, Harding S, Ferro CJ, Kalra PA, Taal MW, Cockwell P.

PLoS Med. 2020 Feb 28;17(2):e1003050. doi: 10.1371/journal.pmed.1003050. eCollection 2020 Feb.

4.

Myocardial characterization in pre-dialysis chronic kidney disease: a study of prevalence, patterns and outcomes.

Price AM, Hayer MK, Vijapurapu R, Fyyaz SA, Moody WE, Ferro CJ, Townend JN, Steeds RP, Edwards NC.

BMC Cardiovasc Disord. 2019 Dec 16;19(1):295. doi: 10.1186/s12872-019-1256-3.

5.

Sudden cardiac death in chronic renal disease: aetiology and risk reduction strategies.

Pickup LC, Law JP, Townend JN, Ferro CJ.

Nephrol Dial Transplant. 2019 Nov 20. pii: gfz232. doi: 10.1093/ndt/gfz232. [Epub ahead of print] No abstract available.

PMID:
31747026
6.

Cytomegalovirus seropositivity is independently associated with cardiovascular disease in non-dialysis dependent chronic kidney disease.

Karangizi AHK, Chanouzas D, Fenton A, Moss P, Cockwell P, Ferro CJ, Harper L.

QJM. 2019 Oct 15. pii: hcz258. doi: 10.1093/qjmed/hcz258. [Epub ahead of print]

PMID:
31613364
7.

Erratum to: SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.

Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M.

Nephrol Dial Transplant. 2019 Aug 9. pii: gfz137. doi: 10.1093/ndt/gfz137. [Epub ahead of print] No abstract available.

PMID:
31397476
8.

Arterial stiffness in chronic kidney disease: a modifiable cardiovascular risk factor?

Pickup L, Radhakrishnan A, Townend JN, Ferro CJ.

Curr Opin Nephrol Hypertens. 2019 Nov;28(6):527-536. doi: 10.1097/MNH.0000000000000535.

PMID:
31361609
9.

Is blood pressure measured correctly in dialysis centres? Physicians' and patients' views.

Pappaccogli M, Labriola L, Van der Niepen P, Pruijm M, Vogt L, Halimi JM, Ferro CJ, Halabi G, Phan O, Bullani R, Saudan P, Avdelidou A, Panou E, Papoulidou F, London G, Rossignol P, Sarafidis P, Persu A, Wuerzner G.

Nephrol Dial Transplant. 2019 Sep 1;34(9):1612-1615. doi: 10.1093/ndt/gfz125. No abstract available.

PMID:
31302688
10.

Early effects of kidney transplantation on the heart - A cardiac magnetic resonance multi-parametric study.

Hayer MK, Radhakrishnan A, Price AM, Baig S, Liu B, Ferro CJ, Captur G, Townend JN, Moon JC, Edwards NC, Steeds RP.

Int J Cardiol. 2019 Oct 15;293:272-277. doi: 10.1016/j.ijcard.2019.06.007. Epub 2019 Jun 4.

11.

Assessing bone mineralisation in children with chronic kidney disease: what clinical and research tools are available?

Lalayiannis AD, Crabtree NJ, Fewtrell M, Biassoni L, Milford DV, Ferro CJ, Shroff R.

Pediatr Nephrol. 2019 Jun 25. doi: 10.1007/s00467-019-04271-1. [Epub ahead of print] Review.

PMID:
31240395
12.

Coronary microvascular dysfunction: a key step in the development of uraemic cardiomyopathy?

Radhakrishnan A, Pickup LC, Price AM, Law JP, Edwards NC, Steeds RP, Ferro CJ, Townend JN.

Heart. 2019 Sep;105(17):1302-1309. doi: 10.1136/heartjnl-2019-315138. Epub 2019 Jun 25. Review.

13.

Renal function and the long-term clinical outcomes of cardiac resynchronization therapy with or without defibrillation.

Leyva F, Zegard A, Taylor R, Foley PWX, Umar F, Patel K, Panting J, Ferro CJ, Chalil S, Marshall H, Qiu T.

Pacing Clin Electrophysiol. 2019 Jun;42(6):595-602. doi: 10.1111/pace.13659. Epub 2019 Apr 3.

14.

Erratum.

Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M.

Nephrol Dial Transplant. 2019 Feb 28. pii: gfz047. doi: 10.1093/ndt/gfz047. [Epub ahead of print] No abstract available.

PMID:
30820538
15.

SGLT-2 inhibitors and GLP-1 receptor agonists for nephroprotection and cardioprotection in patients with diabetes mellitus and chronic kidney disease. A consensus statement by the EURECA-m and the DIABESITY working groups of the ERA-EDTA.

Sarafidis P, Ferro CJ, Morales E, Ortiz A, Malyszko J, Hojs R, Khazim K, Ekart R, Valdivielso J, Fouque D, London GM, Massy Z, Ruggenenti P, Porrini E, Wiecek A, Zoccali C, Mallamaci F, Hornum M.

Nephrol Dial Transplant. 2019 Feb 1;34(2):208-230. doi: 10.1093/ndt/gfy407.

PMID:
30753708
16.

Vive les Differences!-A case for optimism in the treatment of patients with heart failure and preserved ejection fraction?

Law JP, Pickup L, Townend JN, Ferro CJ.

Int J Clin Pract. 2019 Jun;73(6):e13307. doi: 10.1111/ijcp.13307. No abstract available.

PMID:
30582265
17.

Author Correction: Lipid management in patients with chronic kidney disease.

Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C.

Nat Rev Nephrol. 2019 Feb;15(2):121. doi: 10.1038/s41581-018-0099-y.

PMID:
30538326
18.

Lipid management in patients with chronic kidney disease.

Ferro CJ, Mark PB, Kanbay M, Sarafidis P, Heine GH, Rossignol P, Massy ZA, Mallamaci F, Valdivielso JM, Malyszko J, Verhaar MC, Ekart R, Vanholder R, London G, Ortiz A, Zoccali C.

Nat Rev Nephrol. 2018 Dec;14(12):727-749. doi: 10.1038/s41581-018-0072-9. Review. Erratum in: Nat Rev Nephrol. 2019 Feb;15(2):121.

PMID:
30361677
19.

Glucocorticoid activation by 11β-hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A cross-sectional study.

Sagmeister MS, Taylor AE, Fenton A, Wall NA, Chanouzas D, Nightingale PG, Ferro CJ, Arlt W, Cockwell P, Hardy RS, Harper L.

Clin Endocrinol (Oxf). 2019 Jan;90(1):241-249. doi: 10.1111/cen.13889. Epub 2018 Nov 15.

20.

A novel biomarker of laminin turnover is associated with disease progression and mortality in chronic kidney disease.

Holm Nielsen S, Guldager Kring Rasmussen D, Brix S, Fenton A, Jesky M, Ferro CJ, Karsdal M, Genovese F, Cockwell P.

PLoS One. 2018 Oct 1;13(10):e0204239. doi: 10.1371/journal.pone.0204239. eCollection 2018.

21.

The host cellular immune response to cytomegalovirus targets the endothelium and is associated with increased arterial stiffness in ANCA-associated vasculitis.

Chanouzas D, Sagmeister M, Dyall L, Sharp P, Powley L, Johal S, Bowen J, Nightingale P, Ferro CJ, Morgan MD, Moss P, Harper L.

Arthritis Res Ther. 2018 Aug 29;20(1):194. doi: 10.1186/s13075-018-1695-8.

22.

Frailty Intervention Trial iN End-Stage patientS on haemodialysis (FITNESS): study protocol for a randomised controlled trial.

Anderson BM, Dutton M, Day E, Jackson TA, Ferro CJ, Sharif A.

Trials. 2018 Aug 24;19(1):457. doi: 10.1186/s13063-018-2842-x.

23.

Subclinical Reactivation of Cytomegalovirus Drives CD4+CD28null T-Cell Expansion and Impaired Immune Response to Pneumococcal Vaccination in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis.

Chanouzas D, Sagmeister M, Faustini S, Nightingale P, Richter A, Ferro CJ, Morgan MD, Moss P, Harper L.

J Infect Dis. 2019 Jan 7;219(2):234-244. doi: 10.1093/infdis/jiy493.

24.

Which anticoagulants should be used for stroke prevention in non-valvular atrial fibrillation and severe chronic kidney disease?

Kalra PA, Burlacu A, Ferro CJ, Covic A.

Curr Opin Nephrol Hypertens. 2018 Nov;27(6):420-425. doi: 10.1097/MNH.0000000000000443. Review.

PMID:
30020140
25.

Chronic kidney disease as a cardiovascular risk factor: lessons from kidney donors.

Price AM, Edwards NC, Hayer MK, Moody WE, Steeds RP, Ferro CJ, Townend JN.

J Am Soc Hypertens. 2018 Jul;12(7):497-505.e4. doi: 10.1016/j.jash.2018.04.010. Epub 2018 May 9. Review.

26.

Association between urinary free light chains and progression to end stage renal disease in chronic kidney disease.

Fenton A, Jesky MD, Webster R, Stringer SJ, Yadav P, Chapple I, Dasgupta I, Harding SJ, Ferro CJ, Cockwell P.

PLoS One. 2018 May 9;13(5):e0197043. doi: 10.1371/journal.pone.0197043. eCollection 2018.

27.

Humoral immunity to memory antigens and pathogens is maintained in patients with chronic kidney disease.

Wall NA, Dominguez-Medina CC, Faustini SE, Cook CN, McClean A, Jesky MD, Perez-Toledo M, Morgan MD, Richter AG, Ferro CJ, Cockwell P, Moss PA, Henderson IR, Harper L, Cunningham AF.

PLoS One. 2018 Apr 16;13(4):e0195730. doi: 10.1371/journal.pone.0195730. eCollection 2018.

28.

Use of oral anticoagulants in patients with atrial fibrillation and renal dysfunction.

Potpara TS, Ferro CJ, Lip GYH.

Nat Rev Nephrol. 2018 May;14(5):337-351. doi: 10.1038/nrneph.2018.19. Epub 2018 Mar 26. Review.

PMID:
29578207
29.

Diffuse Myocardial Interstitial Fibrosis and Dysfunction in Early Chronic Kidney Disease.

Hayer MK, Price AM, Liu B, Baig S, Ferro CJ, Townend JN, Steeds RP, Edwards NC.

Am J Cardiol. 2018 Mar 1;121(5):656-660. doi: 10.1016/j.amjcard.2017.11.041. Epub 2017 Dec 11.

30.

Results of Serial Myocardial Perfusion Imaging in End-Stage Renal Disease.

Moody WE, Lin ELS, Thomson LE, Berman DS, Edwards NC, Holloway B, Ferro CJ, Townend JN, Steeds RP; Birmingham Cardio-Renal Group.

Am J Cardiol. 2018 Mar 1;121(5):661-667. doi: 10.1016/j.amjcard.2017.11.038. Epub 2017 Dec 11.

PMID:
29291889
31.

Fractures in Kidney Transplant Recipients: A Comparative Study Between England and New York State.

Arnold J, Mytton J, Evison F, Gill PS, Cockwell P, Sharif A, Ferro CJ.

Exp Clin Transplant. 2018 Aug;16(4):410-418. doi: 10.6002/ect.2017.0016. Epub 2017 Nov 15.

32.

Premature coronary artery disease and early stage chronic kidney disease.

Price AM, Ferro CJ, Hayer MK, Steeds RP, Edwards NC, Townend JN.

QJM. 2018 Oct 1;111(10):683-686. doi: 10.1093/qjmed/hcx179. Review.

33.

A randomized, multicenter, open-label, blinded end point trial comparing the effects of spironolactone to chlorthalidone on left ventricular mass in patients with early-stage chronic kidney disease: Rationale and design of the SPIRO-CKD trial.

Hayer MK, Edwards NC, Slinn G, Moody WE, Steeds RP, Ferro CJ, Price AM, Andujar C, Dutton M, Webster R, Webb DJ, Semple S, MacIntyre I, Melville V, Wilkinson IB, Hiemstra TF, Wheeler DC, Herrey A, Grant M, Mehta S, Ives N, Townend JN.

Am Heart J. 2017 Sep;191:37-46. doi: 10.1016/j.ahj.2017.05.008. Epub 2017 May 24.

34.

Dialysis Following Transcatheter Aortic Valve Replacement: Risk Factors and Outcomes: An Analysis From the UK TAVI (Transcatheter Aortic Valve Implantation) Registry.

Ferro CJ, Law JP, Doshi SN, de Belder M, Moat N, Mamas M, Hildick-Smith D, Ludman P, Townend JN; UK TAVI Steering Group and the National Institute for Cardiovascular Outcomes Research.

JACC Cardiovasc Interv. 2017 Oct 23;10(20):2040-2047. doi: 10.1016/j.jcin.2017.05.020. Epub 2017 Aug 2.

35.

Serum endotrophin, a type VI collagen cleavage product, is associated with increased mortality in chronic kidney disease.

Fenton A, Jesky MD, Ferro CJ, Sørensen J, Karsdal MA, Cockwell P, Genovese F.

PLoS One. 2017 Apr 12;12(4):e0175200. doi: 10.1371/journal.pone.0175200. eCollection 2017.

36.

Hypertension in dialysis patients: a consensus document by the European Renal and Cardiovascular Medicine (EURECA-m) working group of the European Renal Association-European Dialysis and Transplant Association (ERA-EDTA) and the Hypertension and the Kidney working group of the European Society of Hypertension (ESH).

Sarafidis PA, Persu A, Agarwal R, Burnier M, de Leeuw P, Ferro CJ, Halimi JM, Heine GH, Jadoul M, Jarraya F, Kanbay M, Mallamaci F, Mark PB, Ortiz A, Parati G, Pontremoli R, Rossignol P, Ruilope L, Van der Niepen P, Vanholder R, Verhaar MC, Wiecek A, Wuerzner G, London GM, Zoccali C.

Nephrol Dial Transplant. 2017 Apr 1;32(4):620-640. doi: 10.1093/ndt/gfw433. Review.

PMID:
28340239
37.

Health-Related Quality of Life Impacts Mortality but Not Progression to End-Stage Renal Disease in Pre-Dialysis Chronic Kidney Disease: A Prospective Observational Study.

Jesky MD, Dutton M, Dasgupta I, Yadav P, Ng KP, Fenton A, Kyte D, Ferro CJ, Calvert M, Cockwell P, Stringer SJ.

PLoS One. 2016 Nov 10;11(11):e0165675. doi: 10.1371/journal.pone.0165675. eCollection 2016.

38.

Outcomes After Weekend Admission for Deceased Donor Kidney Transplantation: A Population Cohort Study.

Anderson BM, Mytton JL, Evison F, Ferro CJ, Sharif A.

Transplantation. 2017 Sep;101(9):2244-2252. doi: 10.1097/TP.0000000000001522.

PMID:
27755501
39.

Re: assessment of myocardial fibrosis with T1 mapping MRI.

Hayer MK, Ferro CJ, Townend JN, Steeds RP, Edwards NC.

Clin Radiol. 2016 Dec;71(12):1309-1310. doi: 10.1016/j.crad.2016.09.005. Epub 2016 Oct 10. No abstract available.

PMID:
27733276
40.

SPRINTing towards trials of blood pressure reduction to reduce CKD progression?

Moody WE, Ferro CJ, Townend JN.

Eur Heart J Qual Care Clin Outcomes. 2016 Oct 1;2(4):229-230. doi: 10.1093/ehjqcco/qcw035. No abstract available.

PMID:
29474719
41.

Effect of mineralocorticoid receptor antagonists on proteinuria and progression of chronic kidney disease: a systematic review and meta-analysis.

Currie G, Taylor AH, Fujita T, Ohtsu H, Lindhardt M, Rossing P, Boesby L, Edwards NC, Ferro CJ, Townend JN, van den Meiracker AH, Saklayen MG, Oveisi S, Jardine AG, Delles C, Preiss DJ, Mark PB.

BMC Nephrol. 2016 Sep 8;17(1):127. doi: 10.1186/s12882-016-0337-0. Review.

42.

Associations of Blood Pressure With Geographical Latitude, Solar Radiation, and Ambient Temperature: Results From the Chilean Health Survey, 2009-2010.

Cabrera SE, Mindell JS, Toledo M, Alvo M, Ferro CJ.

Am J Epidemiol. 2016 Jun 1;183(11):1071-3. doi: 10.1093/aje/kww037. Epub 2016 May 5. No abstract available.

PMID:
27188937
43.

Cytomegalovirus infection is associated with an increase in systolic blood pressure in older individuals.

Firth C, Harrison R, Ritchie S, Wardlaw J, Ferro CJ, Starr JM, Deary IJ, Moss P.

QJM. 2016 Sep;109(9):595-600. doi: 10.1093/qjmed/hcw026. Epub 2016 Apr 12.

44.

Risk of post-transplantation diabetes mellitus is greater in South Asian versus Caucasian kidney allograft recipients.

Peracha J, Nath J, Ready A, Tahir S, Parekh K, Hodson J, Ferro CJ, Borrows R, Sharif A.

Transpl Int. 2016 Jun;29(6):727-39. doi: 10.1111/tri.12782. Epub 2016 May 2.

45.

Serum tryptase concentration and progression to end-stage renal disease.

Jesky MD, Stringer SJ, Fenton A, Ng KP, Yadav P, Ndumbo M, McCann K, Plant T, Dasgupta I, Harding SJ, Drayson MT, Redegeld F, Ferro CJ, Cockwell P.

Eur J Clin Invest. 2016 May;46(5):460-74. doi: 10.1111/eci.12622. Epub 2016 Apr 15.

PMID:
26999448
46.

Prognostic Utility of Calcium Scoring as an Adjunct to Stress Myocardial Perfusion Scintigraphy in End-Stage Renal Disease.

Moody WE, Lin EL, Stoodley M, McNulty D, Thomson LE, Berman DS, Edwards NC, Holloway B, Ferro CJ, Townend JN, Steeds RP; Birmingham Cardio-Renal Group.

Am J Cardiol. 2016 May 1;117(9):1387-96. doi: 10.1016/j.amjcard.2016.02.003. Epub 2016 Feb 17.

47.

Results and lessons from the Spironolactone To Prevent Cardiovascular Events in Early Stage Chronic Kidney Disease (STOP-CKD) randomised controlled trial.

Ng KP, Jain P, Gill PS, Heer G, Townend JN, Freemantle N, Greenfield S, McManus RJ, Ferro CJ.

BMJ Open. 2016 Feb 25;6(2):e010519. doi: 10.1136/bmjopen-2015-010519.

48.

Stroke-Related Hospitalization and Mortality After a Kidney Allograft: A Population-Cohort Study.

Ferro CJ, Karim A, Farrugia D, Bagnall D, Begaj I, Ray D, Sharif A.

Exp Clin Transplant. 2016 Feb;14(1):50-7.

49.

Modulation of stroke risk in chronic kidney disease.

Arnold J, Sims D, Ferro CJ.

Clin Kidney J. 2016 Feb;9(1):29-38. doi: 10.1093/ckj/sfv136. Epub 2015 Dec 23.

50.

Cardiovascular Effects of Unilateral Nephrectomy in Living Kidney Donors.

Moody WE, Ferro CJ, Edwards NC, Chue CD, Lin EL, Taylor RJ, Cockwell P, Steeds RP, Townend JN; CRIB-Donor Study Investigators.

Hypertension. 2016 Feb;67(2):368-77. doi: 10.1161/HYPERTENSIONAHA.115.06608.

Supplemental Content

Loading ...
Support Center